Latest News on AUPH

Financial News Based On Company


Advertisement
Advertisement

An automatic tax sale leaves Aurinia (AUPH) legal chief holding 576,981 shares directly.

https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-6528b39e0e3f.html
Aurinia Pharmaceuticals Inc.'s Chief Legal Officer, Stephen P. Robertson, had 11,867 common shares automatically sold on November 13, 2026, to cover tax withholding obligations. The shares were sold at a weighted-average price of $15.97 per share, related to the vesting of Performance Stock Units from a February 2025 award. After this transaction, Robertson directly holds 576,981 shares of the company's common stock.

(AUPH) Price Dynamics and Execution-Aware Positioning

https://news.stocktradersdaily.com/news_release/78/AUPH_Price_Dynamics_and_Execution-Aware_Positioning_111526065402_1794743642.html
This report analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), identifying weak near and mid-term sentiment but a neutral long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss levels. The analysis highlights an exceptional 32.5:1 risk-reward setup, targeting an 8.6% gain against 0.3% risk.

Aurinia Pharmaceuticals stock gets lift from higher 2026 outlook

https://www.ad-hoc-news.de/boerse/news/nebenwerte/aurinia-pharmaceuticals-stock-gets-lift-from-higher-2026-outlook/70460290
Aurinia Pharmaceuticals saw its stock rise after reporting strong third-quarter results and raising its 2026 revenue outlook. The company's revenue increased 14% year-over-year, driven by LUPKYNIS sales, and it is expanding its autoimmune drug pipeline with the PRESERVE Phase 4 study and continued development of aritinercept. The updated guidance for 2026 total revenue is now between $325 million and $330 million.

Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)

https://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/8640349/analysts-are-bullish-on-these-healthcare-stocks-aurinia-pharmaceuticals-auph-abbvie-abbv/
Two healthcare stocks, Aurinia Pharmaceuticals (AUPH) and AbbVie (ABBV), have received bullish sentiments from analysts. Bloom Burton analyst David Martin PhD maintained a Buy rating on Aurinia Pharmaceuticals with a $21.00 price target, while BMO Capital's Evan Seigerman maintained a Buy rating on AbbVie with a $340.00 price target. Both companies are seen as having upside potential based on current analyst consensus.

TD Cowen maintains Buy on Aurinia Pharmaceuticals, lifts price target to $18

https://scanx.trade/stock-market-news/companies/td-cowen-maintains-buy-aurinia-pharmaceuticals-lifts-price-target-18/54137188
TD Cowen has reaffirmed its Buy rating for Aurinia Pharmaceuticals and increased its price target from $17 to $18, reflecting higher valuation expectations. This update follows an earlier report about Aurinia's settlement with Teva, which prevents the launch of a generic voclosporin until December 2036, extending Aurinia's market exclusivity for its flagship drug, LUPKYNIS. Despite resolving the dispute with Teva, Aurinia still faces ongoing patent infringement litigation from other generic manufacturers.
Advertisement

RBC Capital maintains Aurinia Pharmaceuticals at Sector Perform, raises price target to $18 from $16

https://www.tradingview.com/news/tradingview:f4989601056e3:0-rbc-capital-maintains-aurinia-pharmaceuticals-at-sector-perform-raises-price-target-to-18-from-16/
RBC Capital has reaffirmed its "Sector Perform" rating for Aurinia Pharmaceuticals (AUPH) and increased its price target from $16 to $18. This new target implies an 8.1% upside from the stock's closing price of $16.65 on October 30. Investors can find more details on price target data and analyst ratings on TradingView's Forecasts tab.

RBC Capital maintains Aurinia Pharmaceuticals at Sector Perform, raises price target to $18 from $16

https://www.tradingview.com/news/tradingview:de2751fe567b6:0-rbc-capital-maintains-aurinia-pharmaceuticals-at-sector-perform-raises-price-target-to-18-from-16/
RBC Capital has reaffirmed its "Sector Perform" rating for Aurinia Pharmaceuticals (AUPH) and increased its price target from $16 to $18. This new price target suggests an 8.1% upside from the stock's closing price of $16.65 on October 30. Investors can find more detailed analyst ratings and price target data for Aurinia Pharmaceuticals on TradingView's platform.

Aurinia Pharmaceuticals Narrows 2026 Net Product Sales View to $310M-$315M From $305M-$315M >AUPH

https://www.moomoo.com/news/post/1003010787/aurinia-pharmaceuticals-narrows-2026-net-product-sales-view-to-310m
Aurinia Pharmaceuticals (AUPH) has updated its net product sales outlook for 2026, narrowing the previous range of $305 million to $315 million to a new, more precise range of $310 million to $315 million. This adjustment indicates a slight upward revision at the lower end of their sales expectations for the year.

Aurinia lifts 2026 guidance as LUPKYNIS growth, cash flow and pipeline momentum build

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8573419/aurinia-lifts-2026-guidance-as-lupkynis-growth-cash-flow-and-pipeline-momentum-build/
Aurinia Pharmaceuticals announced strong third-quarter 2026 results, reporting $83.7 million in revenue and raising its full-year 2026 revenue guidance to $325 million–$330 million, primarily due to robust LUPKYNIS sales. The company also initiated a Phase 4 study for LUPKYNIS and advanced aritinercept in its pipeline, expanding its presence in nephrology and autoimmune markets. Analyst Spark rates AUPH as "Outperform," citing strong financials and favorable valuation.

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance By Investing.com

https://za.investing.com/news/stock-market-news/aurinia-pharmaceuticals-stock-falls-3-on-q3-miss-soft-guidance-93CH-4539103
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported third-quarter results that missed analyst expectations for both earnings per share and revenue. Despite raising its full-year 2026 total revenue guidance, the new midpoint still fell below consensus, causing the stock to decline by over 3% in pre-market trading. The company also announced an ongoing Phase 4 study for its lupus nephritis therapy, LUPKYNIS.
Advertisement

A drugmaker raises its 2026 revenue forecast to $325 million–$330 million

https://www.stocktitan.net/news/AUPH/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-yvutpdyg6j3h.html
Aurinia Pharmaceuticals Inc. announced its financial results for the three and nine months ended September 30, 2026, reporting significant revenue and net product sales growth. The company increased its total revenue guidance for 2026 to a range of $325 million to $330 million and narrowed its net product sales guidance to $310 million to $315 million. Additionally, Aurinia provided updates on its clinical development progress, including the initiation of the PRESERVE study for LUPKYNIS in lupus nephritis and the expansion of aritinercept into four potential indications.

Aurinia Revenue Rises on Strong LUPKYNIS Sales and Partner Income

https://www.tipranks.com/news/company-announcements/aurinia-revenue-rises-on-strong-lupkynis-sales-and-partner-income
Aurinia Pharmaceuticals reported robust revenue growth for the three and nine months ending September 30, 2026, driven primarily by strong sales of its lupus nephritis therapy, LUPKYNIS, and increasing income from license, collaboration, and royalty agreements. The company's total revenue rose 14% quarterly and 19% year-to-date, with LUPKYNIS sales up 12% and 18% respectively, and partner-driven income streams growing even faster, diversifying its revenue base. TipRanks' AI Analyst, Spark, rates AUPH as "Outperform" due to strong financial performance and favorable valuation.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

https://www.biospace.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2026-and-provides-update-on-recent-business-progress
Aurinia Pharmaceuticals announced strong financial results for the three and nine months ended September 30, 2026, with total revenue increasing by 14% and 19% respectively, and net product sales of LUPKYNIS growing by 12% and 18%. The company also raised its 2026 total revenue guidance to a range of $325 million to $330 million. Additionally, Aurinia provided updates on its clinical programs, including the initiation of the PRESERVE Phase 4 study for LUPKYNIS in lupus nephritis and the clinical development of aritinercept for autoimmune diseases.

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

https://www.investing.com/news/earnings/aurinia-pharmaceuticals-stock-falls-3-on-q3-miss-soft-guidance-93CH-4987394
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported third-quarter results that fell short of analyst expectations, leading to a 3.43% decline in pre-market trading. The company missed on adjusted earnings per share and revenue estimates, although LUPKYNIS net product sales showed a 12% year-over-year increase. Despite raising its full-year 2026 total revenue guidance, the new midpoint remains below analyst consensus.

Form 8K Aurinia Pharmaceuticals Inc. For: 30 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-aurinia-pharmaceuticals-inc-for-30-october-93CH-4917868
This article reports that Aurinia Pharmaceuticals Inc. filed a Form 8K on October 30, 2026. The filing is a standard regulatory disclosure for significant events that shareholders should know about. The article provides the title of the filing and mentions the stock symbol AUPH, which experienced a -3.25% change.
Advertisement

AUPH Q3'26 Earnings: EPS estimate is 0.22 USD

https://www.tradingview.com/news/tradingview:0ff9d1f70dae0:0-auph-q3-26-earnings-eps-estimate-is-0-22-usd/
Aurinia Pharmaceuticals Inc (AUPH) is scheduled to announce its Q3'26 earnings on October 29, 2026, with an estimated release time of 8:00 AM ET (12:00 PM UTC). Analysts project Q3'26 revenue to be 83.61 million USD and earnings per share (EPS) to be 0.22 USD. The article also provides historical revenue and EPS data, including reported figures, estimates, and surprise percentages for previous quarters.

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

https://au.finance.yahoo.com/news/earnings-preview-aurinia-pharmaceuticals-auph-130015283.html
Aurinia Pharmaceuticals (AUPH) is expected to report a year-over-year decline in Q3 earnings despite higher revenues. The Zacks Consensus Estimate projects quarterly earnings of $0.20 per share, a 13% decline, with revenues of $87.2 million, an 18.7% increase. The company's Earnings ESP is 0%, and with a Zacks Rank #3, it's difficult to conclusively predict an earnings beat, despite a strong history of surpassing EPS estimates.

Aurinia Pharmaceuticals Inc Estimates – NASDAQ:AUPH

https://www.tradingview.com/symbols/NASDAQ-AUPH/financials-estimates/
This page provides an overview of Aurinia Pharmaceuticals Inc (AUPH) financial data and analyst estimates, including income statement, balance sheet, cash flow, and valuation metrics. Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time for both annual and quarterly periods. The platform also offers disclaimers stating that the information is not investment advice and encourages users to conduct their own research.

Aurinia Pharmaceuticals Inc. Estimates – LSE:0UJF

https://www.tradingview.com/symbols/LSE-0UJF/financials-estimates/
This article provides an overview of Aurinia Pharmaceuticals Inc. (LSE:0UJF) on TradingView, focusing on financial actuals and estimates. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Aurinia Pharmaceuticals (AUPH) Stock Looks Below Fair Value After A 136% Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-auph-stock-looks-below-fair-value-af
Aurinia Pharmaceuticals (AUPH) has experienced a significant 136.4% return for shareholders over the past three years. Despite this strong performance, the stock's current P/E ratio of 7.3x is well below the biotech industry average, suggesting it might be undervalued based on its earnings. The article encourages investors to consider the durability of current profits and the potential for its drug portfolio, particularly Lupkynis, to generate repeatable earnings to justify its valuation.
Advertisement

AUPH Q3'26 Earnings: revenue estimate is 83.61M USD

https://www.tradingview.com/news/tradingview:9cf43691be511:0-auph-q3-26-earnings-revenue-estimate-is-83-61m-usd/
Aurinia Pharmaceuticals Inc (AUPH) is projected to announce its Q3'26 financial results on October 29th, with an estimated revenue of $83.61 million and an EPS of $0.22. The report highlights past performance, showing consistent revenue surprises and positive EPS surprises in previous quarters. This upcoming announcement provides key insights into the company's financial trajectory.

TD Cowen maintains Buy rating on Aurinia Pharmaceuticals, $18 price target

https://www.tradingview.com/news/tradingview:c31dc8c6b7338:0-td-cowen-maintains-buy-rating-on-aurinia-pharmaceuticals-18-price-target/
TD Cowen has reiterated its Buy rating on Aurinia Pharmaceuticals (AUPH) with an $18 price target, indicating a 7.5% upside from the October 20 closing price. The key reasons cited are the durable growth of LUPKYNIS, an FDA-approved oral therapy for lupus nephritis, and strong patent protection for the treatment protocol extending into the late 2030s. This protection is expected to reduce generic competition and support long-term revenue.

TD Cowen raises Aurinia Pharmaceuticals price target on cost outlook

https://www.investing.com/news/analyst-ratings/td-cowen-raises-aurinia-pharmaceuticals-price-target-on-cost-outlook-93CH-4962389
TD Cowen has increased its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $18 from $17, maintaining a Buy rating, citing an updated share count and revised R&D cost estimates for 2026. The firm anticipates continued growth for Lupkynis and projects 2026 R&D costs to be $60 million, down from $65 million. Additionally, Aurinia recently settled a patent dispute with Teva Pharmaceuticals, securing exclusivity for voclosporin until at least December 7, 2036.

Aurinia sets November 3 results. Aurinia Pharmaceuticals stock sits 13.35 percent below its high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/aurinia-sets-november-3-results-aurinia-pharmaceuticals-stock-sits-13-35/70377580
Aurinia Pharmaceuticals has scheduled its third-quarter results announcement for November 3, 2026, with an expected revenue of USD 83.61 million. Analysts anticipate a 13.81% increase in revenue compared to the previous year, while the stock currently trades 13.35% below its 52-week high. The company, which develops therapies for autoimmune diseases, also reported its market capitalization at USD 2.2 billion as of October 20, 2026.

Aurinia sets November 3 results. Aurinia Pharmaceuticals stock sits 13.35 percent below its high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/aurinia-sets-november-3-results-aurinia-pharmaceuticals-stock-sits-13-35-percent-below-its-high/70377580
Aurinia Pharmaceuticals has scheduled its third-quarter results announcement for November 3, 2026, with an expected revenue of USD 83.61 million. The company's stock was trading at EUR 14.87 on October 20, 2026, and is currently 13.35 percent below its 52-week high. Analysts anticipate a 13.81 percent increase in revenue year-over-year for the upcoming report.
Advertisement

Aurinia Pharmaceuticals stock heads toward November 3, 2026 earnings

https://www.ad-hoc-news.de/boerse/news/nebenwerte/aurinia-pharmaceuticals-stock-heads-toward-november-3-2026-earnings/70349717
Aurinia Pharmaceuticals (NASDAQ: AUPH) stock is heading towards its third-quarter 2026 earnings report on November 3, 2026. The company's second-quarter revenue of USD 58.57 million fell below estimates, although diluted earnings per share exceeded expectations. Investors will be focused on revenue conversion and continued earnings generation in the upcoming report.

November 3 earnings carry USD 83.61 million estimate for Aurinia Pharmaceuticals stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/november-3-earnings-carry-usd-83-61-million-estimate-for-aurinia-pharmaceuticals-stock/70333381
Aurinia Pharmaceuticals is estimated to report third-quarter 2026 results on November 3, with an expected revenue of USD 83.61 million and earnings per share of USD 0.22. This revenue estimate represents a 13.80 percent increase from the previous year, although the earnings per share estimate is slightly below the prior year's figure. The company's stock was trading at EUR 14.92 on October 15, 2026, with a trailing P/E ratio of 7.31 and a market capitalization of USD 2.2 billion.

Aurinia Pharmaceuticals plots early exit from Montgomery County lease following leadership overhaul

https://www.bizjournals.com/washington/news/2026/10/08/aurinia-pharmaceuticals-rockville-lease.html
Aurinia Pharmaceuticals is reportedly planning an early departure from its Montgomery County lease after a recent leadership change. The company's new CEO, Kevin Tang, who took over in March, has replaced most of the executive team with leaders from his venture capital firm, signaling a potential shift in the company's operational strategy and location. This follows previous news about the Canadian biotech's activities in Rockville, including layoffs and expansions.

Aurinia Pharmaceuticals stock heads toward its November 3 report

https://www.ad-hoc-news.de/boerse/news/nebenwerte/aurinia-pharmaceuticals-stock-heads-toward-its-november-3-report/70260737
Aurinia Pharmaceuticals is preparing for its third-quarter 2026 earnings report on November 3, 2026. The company exceeded Q2 2026 expectations with USD 0.28 EPS and USD 83.2 million in revenue, leading to increased investor focus on the upcoming report. Analysts currently rate the stock a "Moderate Buy" with a target price of USD 17.67.

Aurinia reports second-quarter profit growth: what it means for Aurinia Pharmaceuticals stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/aurinia-reports-second-quarter-profit-growth-what-it-means-for-aurinia-pharmaceuticals-stock/70246318
Aurinia Pharmaceuticals reported a significant 74% increase in second-quarter net income to $37.40 million, with total revenue up 19% to $83.20 million, driven by strong LUPKYNIS sales. The company maintained its 2026 revenue guidance, indicating a stable growth outlook. Analysts have a "Moderate Buy" consensus with a target price of $17.67, highlighting the company's focus on its primary commercial product, LUPKYNIS, for autoimmune diseases.
Advertisement

Tax-withholding stock sale by Aurinia Pharmaceuticals (AUPH) legal chief

https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-44e9d0e09dbd.html
Aurinia Pharmaceuticals' Chief Legal Officer, Stephen P. Robertson, sold 11,939 shares of common stock at approximately $15.95 per share on September 10, 2026. This automatic sale was executed solely to cover tax withholding obligations associated with the vesting of Performance Stock Units awarded on February 28, 2025. Following the transaction, Robertson directly holds 588,848 shares of the company.

Aurinia Pharmaceuticals (NASDAQ: AUPH) Chief Legal Officer Stephen P. Robertson Disposes 11,939 Shares at $15.95 on September 10, 2026

https://kalkinemedia.com/us/news/announcements/aurinia-pharmaceuticals-nasdaq-auph-chief-legal-officer-stephen-p-robertson-disposes-11939-shares-at-1595-on-september-10-2026
Aurinia Pharmaceuticals' Chief Legal Officer, Stephen P. Robertson, sold 11,939 shares of the company's stock at $15.95 per share on September 10, 2026. This transaction reduced his stake by approximately 2.0%, leaving him with 588,848 shares. The sale details were filed under code S.

Aurinia Settles Teva Patent Case; Launch Earliest 2036 | AUPH Stock News

https://www.stocktitan.net/news/AUPH/aurinia-settles-patent-litigation-with-dsb4blja334r.html
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has reached a settlement with Teva Pharmaceuticals Inc. regarding patent litigation for Teva's generic 7.9 mg voclosporin capsules. Teva has agreed that Aurinia's patents (expiring December 2037) are valid and would be infringed by their product. As a result, Teva can launch its generic voclosporin product no earlier than December 7, 2036, pending FDA approval, while Aurinia continues patent infringement actions against other generic manufacturers.

Aurinia Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/aurinia-pharmaceuticals/employees
Aurinia Pharmaceuticals (NASDAQ: AUPH) had approximately 129 employees worldwide as of March 2026, marking a 58.0% decline from 2023. Despite this reduction in headcount, the company is actively hiring, with 15 active job postings in 2026, a 175.0% increase from the previous year. The workforce is primarily concentrated in North America, and employee sentiment is reported as negative and declining.

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

https://www.benzinga.com/news/26/08/61437722/aurinia-pharmaceuticals-chief-legal-officer-trades-355k-company-stock
Aurinia Pharmaceuticals' Chief Legal Officer, Stephen P. Robertson, sold 20,975 shares of company stock valued at $355,945 on August 26, according to an SEC filing. This insider transaction occurred as Aurinia Pharmaceuticals shares were down 1.55%, trading at $16.74. The company, focused on autoimmune diseases, reported strong revenue growth, high gross margins, positive EPS, and prudent debt management, though its Price to Sales ratio indicates potential overvaluation.
Advertisement

Aurinia (NASDAQ: AUPH) legal chief sells shares to cover taxes

https://www.stocktitan.net/sec-filings/AUPH/form-4-aurinia-pharmaceuticals-inc-insider-trading-activity-0958befae587.html
Aurinia Pharmaceuticals Inc.'s Chief Legal Officer, Stephen P. Robertson, sold 20,975 shares of common stock at a weighted average price of $16.97 per share on August 21, 2026. This transaction was primarily conducted to cover tax withholding obligations associated with the vesting of Performance Stock Units. Following this sale, and including 360 shares acquired through an employee share purchase plan, Robertson beneficially holds 600,787 common shares.

Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes

https://www.stocktitan.net/sec-filings/AUPH/144-aurinia-pharmaceuticals-inc-sec-filing-3592824ebe82.html
Aurinia Pharmaceuticals Inc. (AUPH) officer Stephen P. Robertson plans to sell up to 47,000 common shares on or after August 21, 2026, through Morgan Stanley Smith Barney LLC. This sale is intended to cover tax withholding obligations associated with the vesting of performance stock units. The proposed sale has a neutral impact and sentiment according to Rhea-AI.

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

https://www.easternprogress.com/aurinia-pharmaceuticals-auph-q1-earnings-and-revenues-top-estimates/article_a650f83a-1123-5247-8f3c-8cdad4679fbf.html
Aurinia Pharmaceuticals (AUPH) reported strong Q1 2026 earnings, beating the Zacks Consensus Estimate with $0.25 per share against an expected $0.18. The company also surpassed revenue expectations, bringing in $77.71 million compared to the estimated $77.41 million. Despite these positive results, Aurinia's stock performance year-to-date has lagged the S&P 500, and it currently holds a Zacks Rank #3 (Hold).

Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement

https://finance.biggo.com/news/47c86ce8-936f-43ae-bea0-00e1bcc50e63
Aurinia Pharmaceuticals has reached a patent settlement with Teva Pharmaceutical Industries, preventing Teva from launching a generic version of Lupkynis in the U.S. until December 7, 2036. This agreement removes a significant generic threat, strengthening Aurinia's intellectual property protection and driving an after-hours stock increase of up to 6%. The company still faces litigation from other generic challengers but is advancing its pipeline with new studies and drug candidates.

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

https://uk.finance.yahoo.com/news/aurinia-settles-voclosporin-patent-litigation-162300764.html
Aurinia Pharmaceuticals has settled patent infringement litigation with Teva Pharmaceuticals regarding Teva's generic voclosporin oral capsules. The settlement confirms Aurinia's patents are valid and enforceable, expiring in December 2037, and prevents Teva from launching its generic product before December 7, 2036, pending FDA approval. This agreement provides Aurinia with extended market exclusivity for its voclosporin product, Lupkynis, which is used for lupus nephritis treatment, and resulted in a 6% rise in Aurinia's stock.
Advertisement

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Stock Forecast & Analyst Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/future
Aurinia Pharmaceuticals (AUPH) is forecast to see its earnings decline by 4.8% annually, while revenue is expected to grow by 11.5% per year. The company's lead product, LUPKYNIS, for lupus nephritis, continues to be a primary driver of revenue, and recent patent settlements and clinical data reinforce its market position. Despite strong product sales, risks include future earnings decline, high non-cash earnings, insider selling, and competition, although the company is also expanding its pipeline with new autoimmune therapy candidates.

AUPH: Patent Win And Clinical Progress Will Support A Balanced 2026 Outlook

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/u6qzqcmm-auph-future-opportunities-will-depend-on-pipeline-clarity-and-risk-developments/updates/13-the-analyst-price-target-for-aurinia-pharmaceuticals-has-inc
Aurinia Pharmaceuticals (AUPH) has seen its analyst price target increase to $18.17 following a patent settlement with Teva Pharmaceuticals, robust Q2 2026 financial results, and advancements in its clinical pipeline. The settlement prevents Teva from launching a generic voclosporin product before December 2036, while strong LUPKYNIS sales underpin a positive 2026 outlook despite some adjustments to growth and profitability projections. The company also reported positive Phase 3 study data and continued share repurchases.

TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17

https://www.moomoo.com/news/post/74996247/td-cowen-maintains-aurinia-pharmaceuticals-auphus-with-buy-rating-maintains
TD Cowen has reiterated its Buy rating for Aurinia Pharmaceuticals (AUPH.US), maintaining a target price of $17. This indicates continued confidence from the firm in the company's financial outlook and stock performance.

Aurinia Settles Patent Litigation with Teva

https://finance.yahoo.com/healthcare/articles/aurinia-settles-patent-litigation-teva-200500012.html
Aurinia Pharmaceuticals Inc. has reached a settlement agreement with Teva Pharmaceuticals Inc. regarding patent infringement litigation over Teva's generic voclosporin oral capsules. Under the terms, Teva acknowledges the validity and enforceability of Aurinia's patents (expiring December 2037) and can launch its generic product no earlier than December 7, 2036, pending FDA approval. Aurinia continues its patent infringement actions against several other pharmaceutical companies.

Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules

https://kalkinemedia.com/us/news/announcements/aurinia-pharmaceuticals-and-teva-pharmaceuticals-resolve-patent-litigation-over-generic-voclosporin-capsules
Aurinia Pharmaceuticals Inc. and its subsidiary, Aurinia Pharma U.S., Inc., have reached a settlement agreement with Teva Pharmaceuticals Inc. concerning patent infringement litigation. The dispute was related to Teva's Abbreviated New Drug Application (ANDA) for generic 7.9 mg voclosporin oral capsules. The settlement was announced via a Form 8-K filing on August 19, 2026, though specific financial details or timelines were not disclosed.
Advertisement

AUPH Stock Rallies 6% After-Hours — Here’s Why

https://stocktwits.com/news-articles/markets/equity/auph-stock-rallies-6-after-hours-here-s-why/cZYdw3NRJlt
Aurinia Pharmaceuticals (AUPH) stock rallied after-hours following a patent settlement with Teva Pharmaceuticals regarding its drug LUPKYNIS. The agreement prevents Teva from launching a generic version of LUPKYNIS before December 2036, extending Aurinia's market exclusivity. This news boosted retail investor sentiment, with many anticipating positive outcomes from ongoing litigation and potential buyout interest in Aurinia.

Aurinia stock falls on Teva patent settlement for voclosporin

https://www.investing.com/news/stock-market-news/aurinia-stock-falls-on-teva-patent-settlement-for-voclosporin-93CH-4868185
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares declined 2% after announcing a patent settlement with Teva Pharmaceuticals Inc. The settlement permits Teva to launch a generic version of voclosporin no earlier than December 7, 2036, though this is contingent on FDA approval and other factors. Aurinia's patent infringement actions against several other pharmaceutical companies for generic voclosporin remain ongoing.

(AUPH) Risk Channels and Responsive Allocation

https://news.stocktradersdaily.com/news_release/151/AUPH_Risk_Channels_and_Responsive_Allocation_081526121002_1786767002.html
The article analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment despite potential long-term strength. It details an exceptional 43.3:1 risk-reward setup targeting an 11.7% gain versus 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages

https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09/
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $17.67. This comes despite its CEO and other insiders acquiring a significant number of shares recently. The company beat EPS estimates but missed revenue forecasts in its latest quarterly report.

Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy

https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-nasdaqauph-downgraded-by-wall-street-zen-to-buy-2026-08-08/
Wall Street Zen downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from "strong buy" to "buy" due to revenue falling short of expectations, despite beating EPS estimates. The broader analyst consensus remains "hold" with an average price target of $17.67. Insider buying, including a significant purchase by the CEO, indicates confidence in the company, with insiders owning 10.4% of the stock.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement